This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.

As the U.S. healthcare system works to focus on the move to preventive, personalized care for patients, it’s time to turn the tide on diabetes by addressing the three Cs of chronic disease care: compassion, coordination, and community.

Amazon Pharmacy announced Tuesday that it is launching automatic coupons for more than 15 insulin and diabetes care brands. The move, while incremental, solves a major pain point for consumers with diabetes, as many struggle to afford insulin products.

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

Oura — a company selling a ring that tracks peoples’ biometrics — announced new partnerships with three providers of continuous glucose monitors: January, Supersapiens and Veri. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users’ glucose levels and overall health.

Know Labs recently unveiled the prototype for its non-invasive, portable glucose monitoring device. The device incorporates the company’s proprietary body-radio frequency identification (Bio-RFID) technology — meaning its sensors deploy radio waves that travel through the skin to find and measure molecular signatures in the blood.

With obesity, diabetes, and heart disease rapidly growing among communities of color, we need to do everything we can to help people sustain healthy eating habits. It’ll take more nuance than a Westernized one-size-fits-all diet.

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.

Eli Lilly is selling to Amphastar Pharmaceuticals global rights to Baqsimi, an emergency treatment for severe hypoglycemia in diabetes patients. The deal come as Lilly turns its focus to novel medicines for diabetes and other indications.

Paul Markovich believes in the value of health tech in managing both chronic diseases and in general health and wellness. In this episode, he talks about the company’s Wellvolution platform and the digital tools that are offered there to members, now even to those on Medicaid.

Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.

Eli Lilly is slashing prices for its insulin products and capping a patient’s monthly out-of-pocket costs at $35. But a financial analyst notes that the company can afford to cut prices on older medicines like insulin because the strategy will help it maintain pricing power for innovative new drugs.

Virta is available this month to all Blue Shield of California members enrolled in preferred provider organization plans for individual and family, fully insured, self funded and Medicare Advantage. The payer has been working with Virta since 2019 when the digital health company joined Blue Shield of California’s Wellvolution, a platform of digital lifestyle apps.

Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.

Was Livongo a good business? As Burke, now CEO of Quantum Health, touts its strength to investors ahead of a potential IPO, should the Livongo-Teladoc history give them pause?

About 47% of American adults have hypertension and 14% have diabetes. Yet, 12% of people have set a goal to manage their blood pressure and 6% have a goal to manage their diabetes, a new HealthJoy survey found. Comparatively, about half of Americans have a musculoskeletal condition, and 35% of respondents are interested in managing back or joint pain.

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Medicare Advantage patients with diabetes have higher prescription fill rates, fewer emergency department visits and lower total medical spending than traditional fee-for-service Medicare patients, a new report shows. They also received their diagnosis earlier.

California’s Office of the Attorney General contends that drugmakers and pharmacy benefit managers work together to “aggressively raise the list price of insulin in lockstep with each other to artificial levels.” Insulin manufacturers deny the allegations, pointing to availability of lower-cost versions of their products.

Yes Health provides concierge health coaching and services for weight loss and diabetes prevention, all through its app. After taking a short quiz, members will receive a personalized plan — created by the company’s dietitians, nutritionists, fitness experts and psychologists — to improve their health. The app also offers an AI-powered service where members can take pictures of their meals to receive guidance on how to make them healthier.

To help address the diabetes epidemic, providers should incorporate remote patient monitoring into the standard of care, according to Kaiser Permanente physician Dr. Sos Mboijana. When treating chronic conditions like diabetes, having access to a continuous flow of patient data is critical, he said.

Ochsner Health recently released the results of its digital health pilot program for Medicaid patients with hypertension and type 2 diabetes. The program, which combines remote patient monitoring with personalized care teams, did an efficient job at bringing down patients’ blood pressure and hemoglobin A1c levels.

Should we start treating menopause as a disease condition? In our view, it’s a chronic disease condition that can go beyond two decades for some women, resulting in silent suffering.

This dearth of maternity care providers is exacerbating the country’s less-than-stellar reputation for birth outcomes. In order to ensure better health for mothers and their newborns, OB-GYNs must identify risk factors that negatively impact pregnancy early on and work to maintain the whole picture of their pregnant patients’ health. However, OB-GYNs aren’t incentivized to do this under a fee-for-service payment model.

The American Diabetes Association recently launched the Amputation Prevention Alliance — a three-year effort to decrease the number of diabetes-related amputations in the country — along with five partner organizations. The organizations will work together to advocate for policy changes, increase clinician education about caring for diabetic complications, and improve patients’ awareness of warning signs to watch out for.

RxBenefits, a pharmacy benefits optimizer, and Tria Health, a chronic condition and medication management company, have launched a new partnership to improve diabetes care and lower healthcare costs for the condition through a proactive approach. 

The rising levels of both type 1 and type 2 diabetes in American youth is quickly becoming a major public health concern. To help address this problem, Mount Sinai partnered with mPulse Mobile, a company that offers a AI-based mobile patient messaging platform. Together with a group of teenage community members, they created a text message-based youth diabetes prevention program focused on integrating healthy behaviors into teens’ lives.

The FDA approved Eli Lilly drug Mounjaro as a treatment for type 2 diabetes. The decision gives the pharmaceutical giant a new competitor to a blockbuster drug from rival Novo Nordisk, as well as a successor to its blockbuster diabetes drug Trulicity.

The second quarter of 2022 kicked off with a new life sciences company joining the public markets, but not via an IPO or merger. Becton Dickinson on Friday completed the spinoff of its diabetes care business, Embecta, which now trades on the Nasdaq.

Better Therapeutics reported that its digital therapeutic for type 2 diabetes met the main goal of a pivotal study. An FDA submission is expected in the middle of this year, followed by additional clinical trials testing digital therapeutics developed for other cardiometabolic disorders.